Evidence map›Paper›PMID 26499837›Full record

ArticleMolecular & cellular proteomics : MCP2016

Proteomic Analysis Revealed the Important Role of Vimentin in Human Cervical Carcinoma HeLa Cells Treated With Gambogic Acid.

Qingxi Yue, Lixing Feng, Biyin Cao, Miao Liu, Dongmei Zhang, Wanying Wu, Baohong Jiang, Min Yang, Xuan Liu, Dean Guo

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular & cellular proteomics : MCP, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
7.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 37 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Gambogic acid: A shining natural compound to nanomedicine for cancer therapeutics.Biochimica et biophysica acta. Reviews on cancer · 2020
    Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Gambogic acid identifies an isoform-specific druggable pocket in the middle domain of Hsp90β.Proceedings of the National Academy of Sciences of the United States of America · 2016
    Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Qingxi YueFrom the ‡Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China; §Institute of Oncology, Shanghai 9th People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; ¶College of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Shanghai, China; qxyue@sibs.ac.cn.
Lixing FengFrom the ‡Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China;
Biyin Cao‖College of Pharmaceutical Sciences, Soochow University, Suzhou, China.
Miao LiuFrom the ‡Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China;
Dongmei ZhangFrom the ‡Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China;
Wanying WuFrom the ‡Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China;
Baohong JiangFrom the ‡Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China;
Min YangFrom the ‡Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China;
Xuan LiuFrom the ‡Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China;
Dean GuoFrom the ‡Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China; ¶College of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Shanghai, China;
Shanghai Institute of Materia Medica · CNChinese Academy of Sciences · CNSoochow University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gambogic acid (GA) is an anticancer agent in phase IIb clinical trial in China. In HeLa cells, GA inhibited cell proliferation, induced cell cycle arrest at G2/M phase and apoptosis, as showed by results of MTT assay and flow cytometric analysis. Possible target-related proteins of GA were searched using comparative proteomic analysis (2-DE) and nine proteins at early (3 h) stage together with nine proteins at late (24 h) stage were found. Vimentin was the only target-related protein found at both early and late stage. Results of both 2-DE analysis and Western blotting assay suggested cleavage of vimentin induced by GA. MS/MS analysis of cleaved vimentin peptides indicated possible cleavage sites of vimentin at or near ser51 and glu425. Results of targeted proteomic analysis showed that GA induced change in phosphorylation state of the vimentin head domain (aa51-64). Caspase inhibitors could not abrogate GA-induced cleavage of vimentin. Over-expression of vimentin ameliorated cytotoxicity of GA in HeLa cells. The GA-activated signal transduction, from p38 MAPK, heat shock protein 27 (HSP27), vimentin, dysfunction of cytoskeleton, to cell death, was predicted and then confirmed. Results of animal study showed that GA treatment inhibited tumor growth in HeLa tumor-bearing mice and cleavage of vimentin could be observed in tumor xenografts of GA-treated animals. Results of immunohistochemical staining also showed down-regulated vimentin level in tumor xenografts of GA-treated animals. Furthermore, compared with cytotoxicity of GA in HeLa cells, cytotoxicity of GA in MCF-7 cells with low level of vimentin was weaker whereas cytotoxicity of GA in MG-63 cells with high level of vimentin was stronger. These results indicated the important role of vimentin in the cytotoxicity of GA. The effects of GA on vimentin and other epithelial-to-mesenchymal transition (EMT) markers provided suggestion for better usage of GA in clinic.

Indexed as

AnimalsApoptosisBlotting, WesternCell Line, TumorCell ProliferationCell SurvivalElectrophoresis, Gel, Two-DimensionalFemaleG2 Phase Cell Cycle CheckpointsHeLa CellsHumansMCF-7 CellsMice, NudeMicroscopy, ConfocalProteomeProteomicsgambogic acidProteomeVimentinXanthones

Identifiers

PMID26499837
PMCPMC4762520
OpenAlexW2176788997

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.